PYPD
PolyPid Ltd.
Biotechnology
Market Cap$81M
5Y Perf.-99.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PYPD vs CLDX
Revenue, margins, valuation, and 5-year total return — side by side.
CLDX
Celldex Therapeutics, Inc.
Biotechnology
Market Cap$2.22B
5Y Perf.+161.3%
PYPD vs CLDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PYPD | CLDX |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $81M | $2.22B |
| Revenue (TTM) | $0.00 | $2M |
| Net Income (TTM) | $-34M | $-259M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -191.6% |
| Total Debt | $3M | $2M |
| Cash & Equiv. | $6M | $29M |
PYPD vs CLDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PYPD
CLDX
| Stock | Jun 20 | May 26 | Return |
|---|---|---|---|
| PolyPid Ltd. (PYPD) | 100 | 0.8 | -99.2% |
| Celldex Therapeutic… (CLDX) | 100 | 261.3 | +161.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PYPD vs CLDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PYPD leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Celldex Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
PYPD
PolyPid Ltd.
The Income Pick
PYPD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.11
- EPS growth 57.4%
- Lower volatility, beta 1.11, Low D/E 25.5%, current ratio 1.97x
Best for: income & stability and growth exposure
CLDX
Celldex Therapeutics, Inc.
The Long-Run Compounder
CLDX is the clearest fit if your priority is long-term compounding.
- -43.3% 10Y total return vs PYPD's -99.2%
- +76.2% vs PYPD's +57.3%
- -38.9% ROA vs PYPD's -153.2%, ROIC -35.2% vs -5.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PYPD | -2.9% revenue growth vs CLDX's -78.6% |
| Quality / Margins | PYPD | -3.1% margin vs CLDX's -172.5% |
| Stability / Safety | PYPD | Beta 1.11 vs CLDX's 1.73 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CLDX | +76.2% vs PYPD's +57.3% |
| Efficiency (ROA) | CLDX | -38.9% ROA vs PYPD's -153.2%, ROIC -35.2% vs -5.5% |
PYPD vs CLDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PYPD vs CLDX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCLDXLAGGINGPYPD
PYPDPolyPid Ltd.
0leads
CLDXCelldex Therapeutics,…
3leads
6 Total Categories
CATEGORYLEADERvs PYPDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
CLDX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CLDX7/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CLDX6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
CLDX and PYPD operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | PYPDPolyPid Ltd. | CLDXCelldex Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2M |
| EBITDAEarnings before interest/tax | -$15M | -$284M |
| Net IncomeAfter-tax profit | -$34M | -$259M |
| Free Cash FlowCash after capex | $0 | -$213M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -191.6% |
| Net MarginNet income ÷ Revenue | — | -172.5% |
| FCF MarginFCF ÷ Revenue | — | -142.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -93.6% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -73.2% |
Insufficient data to determine a leader in this category.
Valuation Metrics
CLDX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | PYPDPolyPid Ltd. | CLDXCelldex Therapeut… |
|---|---|---|
| Market CapShares × price | $81M | $2.2B |
| Enterprise ValueMkt cap + debt − cash | $77M | $2.2B |
| Trailing P/EPrice ÷ TTM EPS | -2.12x | -8.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1477.19x |
| Price / BookPrice ÷ Book value/share | 6.61x | 4.20x |
| Price / FCFMarket cap ÷ FCF | — | — |
CLDX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
CLDX leads this category, winning 7 of 7 comparable metrics.
Profitability & Efficiency
CLDX delivers a -41.7% return on equity — every $100 of shareholder capital generates $-42 in annual profit, vs $-3 for PYPD. CLDX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PYPD's 0.25x.
| Metric | PYPDPolyPid Ltd. | CLDXCelldex Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -3.1% | -41.7% |
| ROA (TTM)Return on assets | -153.2% | -38.9% |
| ROICReturn on invested capital | -5.5% | -35.2% |
| ROCEReturn on capital employed | -2.4% | -44.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.25x | 0.00x |
| Net DebtTotal debt minus cash | -$4M | -$27M |
| Cash & Equiv.Liquid assets | $6M | $29M |
| Total DebtShort + long-term debt | $3M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -27.47x | — |
CLDX leads this category, winning 7 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CLDX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CLDX five years ago would be worth $12,201 today (with dividends reinvested), compared to $168 for PYPD. Over the past 12 months, CLDX leads with a +76.2% total return vs PYPD's +57.3%. The 3-year compound annual growth rate (CAGR) favors CLDX at -0.0% vs PYPD's -29.1% — a key indicator of consistent wealth creation.
| Metric | PYPDPolyPid Ltd. | CLDXCelldex Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | +2.0% | +23.4% |
| 1-Year ReturnPast 12 months | +57.3% | +76.2% |
| 3-Year ReturnCumulative with dividends | -64.3% | -0.1% |
| 5-Year ReturnCumulative with dividends | -98.3% | +22.0% |
| 10-Year ReturnCumulative with dividends | -99.2% | -43.3% |
| CAGR (3Y)Annualised 3-year return | -29.1% | -0.0% |
CLDX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PYPD and CLDX each lead in 1 of 2 comparable metrics.
Risk & Volatility
PYPD is the less volatile stock with a 1.11 beta — it tends to amplify market swings less than CLDX's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLDX currently trades 93.1% from its 52-week high vs PYPD's 86.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PYPDPolyPid Ltd. | CLDXCelldex Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.69x |
| 52-Week HighHighest price in past year | $5.12 | $35.79 |
| 52-Week LowLowest price in past year | $2.44 | $17.85 |
| % of 52W HighCurrent price vs 52-week peak | +86.6% | +93.1% |
| RSI (14)Momentum oscillator 0–100 | 50.3 | 60.7 |
| Avg Volume (50D)Average daily shares traded | 51K | 985K |
Evenly matched — PYPD and CLDX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PYPDPolyPid Ltd. | CLDXCelldex Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $48.00 |
| # AnalystsCovering analysts | — | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CLDX leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.
Best OverallCelldex Therapeutics, Inc. (CLDX)Leads 3 of 6 categories
Loading custom metrics...
PYPD vs CLDX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PYPD or CLDX a better buy right now?
Analysts rate Celldex Therapeutics, Inc.
(CLDX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PYPD or CLDX?
Over the past 5 years, Celldex Therapeutics, Inc.
(CLDX) delivered a total return of +22. 0%, compared to -98. 3% for PolyPid Ltd. (PYPD). Over 10 years, the gap is even starker: CLDX returned -42. 2% versus PYPD's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PYPD or CLDX?
By beta (market sensitivity over 5 years), PolyPid Ltd.
(PYPD) is the lower-risk stock at 1. 10β versus Celldex Therapeutics, Inc. 's 1. 69β — meaning CLDX is approximately 54% more volatile than PYPD relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 25% for PolyPid Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — PYPD or CLDX?
On earnings-per-share growth, the picture is similar: PolyPid Ltd.
grew EPS 57. 4% year-over-year, compared to -59. 2% for Celldex Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PYPD or CLDX?
PolyPid Ltd.
(PYPD) is the more profitable company, earning 0. 0% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PYPD leads at 0. 0% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — CLDX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PYPD or CLDX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PYPD or CLDX better for a retirement portfolio?
For long-horizon retirement investors, PolyPid Ltd.
(PYPD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Celldex Therapeutics, Inc. (CLDX) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PYPD: -99. 2%, CLDX: -42. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PYPD and CLDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.